Ablynx, Protagonist Report Phase II Failures

Ablynx and Protagonist Therapeutics today acknowledged mid-stage trial failures, with both companies saying they are evaluating the future of the pipeline candidates that generated the disappointing clinical results.Ablynx—which is being acquired by Sanofi for €3.9 billion ($4.8 billion)—disclosed that its systemic lupus erythematosus (SLE) candidate vobarilizumab missed its primary endpoint of dose response in the Phase II STEADY SLE dose-ranging study based on the modified BIL